Form 4: Xenon Pharmaceuticals Executive Granted Stock Options

James R. Empfield, EVP of Drug Discovery at Xenon Pharmaceuticals, was granted stock options for 65,000 common shares on March 11, 2024.

Summary

• James R. Empfield, the EVP of Drug Discovery at Xenon Pharmaceuticals Inc. (XENE), was granted stock options on March 11, 2024.
• The stock options grant him the right to buy 65,000 common shares at an exercise price of $44.37.
• The options vest 25% on January 1, 2025, and the remaining 75% vest over the subsequent three years in equal monthly installments.
• Empfield also granted a Power of Attorney to Sherry Aulin, Andrea DiFabio, Ilona Lo, and Nathaniel Adams to handle SEC filings on his behalf.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a stock option grant. However, such grants are generally viewed positively as they align executive interests with shareholder value.

Positives

• The granting of stock options to a key executive like the EVP of Drug Discovery can be seen as an incentive to align their interests with the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the stock option grant suggests an expectation of continued contributions from the executive.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize key employees and align their interests with the company's performance. This grant is part of Xenon Pharmaceuticals' overall compensation strategy.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term value creation.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to improve company performance.
• The executive benefits from the potential to profit from future stock price appreciation.

Key Dates